glimepiride has been researched along with Diabetic Angiopathies in 15 studies
glimepiride: structure given in first source
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 9.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 5.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| "Patients aged 35-70 years with poorly controlled diabetes [fasting plasma glucose (FPG) > or =1,40 g/l and < 3 g/l at baseline] were treated with glimepiride for 6 months, with dosage titrated from 1-6 mg daily, depending on the monthly FPG measurement." | 2.70 | Predictors of response to glimepiride in patients with type 2 diabetes mellitus. ( Altman, JJ; Charpentier, G; Derobert, E; Etienne, S; Fleury, F; Grimaldi, A; Halimi, S; Oriol, V; Vaur, L, 2001) |
| "Treatment with pioglitazone produced improvement in several parameters, such as systolic blood pressure and lipid levels, including a 14% increase in HDL cholesterol, and reduced CIMT progression, compared with glimepiride." | 2.45 | The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus. ( Davidson, M; Mazzone, T; Polonsky, T, 2009) |
| "Glimepiride was associated with the best clinical outcome, showing the lowest mortality and lowest cardiovascular event risk of the five insulin secretagogues." | 1.51 | Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. ( Huang, HK; Yeh, JI, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leonard, CE | 1 |
| Brensinger, CM | 1 |
| Aquilante, CL | 1 |
| Bilker, WB | 1 |
| Boudreau, DM | 1 |
| Deo, R | 1 |
| Flory, JH | 1 |
| Gagne, JJ | 1 |
| Mangaali, MJ | 1 |
| Hennessy, S | 1 |
| Huang, HK | 1 |
| Yeh, JI | 1 |
| Wang, B | 1 |
| Zhong, J | 1 |
| Lin, H | 1 |
| Zhao, Z | 1 |
| Yan, Z | 1 |
| He, H | 1 |
| Ni, Y | 1 |
| Liu, D | 1 |
| Zhu, Z | 1 |
| Nitta, Y | 2 |
| Tahara, N | 2 |
| Tahara, A | 2 |
| Honda, A | 1 |
| Kodama, N | 2 |
| Mizoguchi, M | 2 |
| Kaida, H | 2 |
| Ishibashi, M | 2 |
| Hayabuchi, N | 2 |
| Ikeda, H | 2 |
| Yamagishi, S | 2 |
| Imaizumi, T | 2 |
| Jax, T | 1 |
| Stirban, A | 1 |
| Terjung, A | 1 |
| Esmaeili, H | 1 |
| Berk, A | 1 |
| Thiemann, S | 1 |
| Chilton, R | 1 |
| von Eynatten, M | 1 |
| Marx, N | 1 |
| Jojima, T | 1 |
| Suzuki, K | 1 |
| Hirama, N | 1 |
| Uchida, K | 1 |
| Hattori, Y | 1 |
| Duckworth, W | 1 |
| Abraira, C | 1 |
| Moritz, T | 1 |
| Reda, D | 1 |
| Emanuele, N | 1 |
| Reaven, PD | 1 |
| Zieve, FJ | 1 |
| Marks, J | 1 |
| Davis, SN | 1 |
| Hayward, R | 1 |
| Warren, SR | 1 |
| Goldman, S | 1 |
| McCarren, M | 1 |
| Vitek, ME | 1 |
| Henderson, WG | 1 |
| Huang, GD | 1 |
| Polonsky, T | 1 |
| Mazzone, T | 1 |
| Davidson, M | 1 |
| Nagayama, D | 1 |
| Saiki, A | 1 |
| Endo, K | 1 |
| Yamaguchi, T | 1 |
| Ban, N | 1 |
| Kawana, H | 1 |
| Ohira, M | 1 |
| Oyama, T | 1 |
| Miyashita, Y | 1 |
| Shirai, K | 1 |
| Tawakol, A | 1 |
| Finn, AV | 1 |
| Oba, T | 1 |
| Mawatari, K | 1 |
| Yasukawa, H | 1 |
| Harada, H | 1 |
| Marwick, TH | 1 |
| Narula, J | 1 |
| Skugor, M | 1 |
| Siraj, ES | 1 |
| Rizzo, MR | 1 |
| Barbieri, M | 1 |
| Grella, R | 1 |
| Passariello, N | 1 |
| Paolisso, G | 1 |
| Charpentier, G | 1 |
| Vaur, L | 1 |
| Halimi, S | 1 |
| Fleury, F | 1 |
| Derobert, E | 1 |
| Grimaldi, A | 1 |
| Oriol, V | 1 |
| Etienne, S | 1 |
| Altman, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631] | 70 participants (Actual) | Interventional | 2007-05-31 | Completed | |||
| International Multicenter Trial on the Prognostic Value of Arterial 18F-FDG PET Imaging in Patients With History of Myocardial Infarction[NCT05138718] | 2,041 participants (Anticipated) | Observational [Patient Registry] | 2021-12-01 | Recruiting | |||
| Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA')[NCT01703286] | Phase 1 | 42 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)[NCT00032487] | Phase 3 | 1,791 participants (Actual) | Interventional | 2000-12-01 | Completed | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm
| Intervention | percentage (Mean) |
|---|---|
| Linagliptin 5 mg | 1.003 |
| Glimepiride 1-4 mg | 1.053 |
| Placebo | 0.981 |
Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm
| Intervention | Percentage (Geometric Mean) |
|---|---|
| Linagliptin 5 mg | 1.262 |
| Glimepiride 1-4 mg | 1.045 |
| Placebo | 1.009 |
Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm
| Intervention | percentage (Geometric Mean) |
|---|---|
| Linagliptin 5 mg | 0.885 |
| Glimepiride 1-4 mg | 1.002 |
| Placebo | 1.002 |
Number of patients with any adverse events (NCT01703286)
Timeframe: up to 20 weeks
| Intervention | participants (Number) |
|---|---|
| Linagliptin 5 mg | 11 |
| Glimepiride 1-4 mg | 25 |
| Placebo | 14 |
| REP - Linagliptin 5 mg | 4 |
| REP - Glimepiride 1-4 mg | 7 |
| Rep - Placebo | 7 |
Myocardial infarction (MI), intervention for coronary artery or Peripheral Vascular Disease (PVD), severe inoperable Coronary Artery Disease (CAD), new or worsening Congestive Heart Failure (CHF), stroke, Cardiovascular (CV) death, or amputation for ischemic gangrene. (NCT00032487)
Timeframe: Post baseline time to the first major macrovascular event up to 82 months
| Intervention | participants (Number) |
|---|---|
| Arm 1 | 264 |
| Arm 2 | 235 |
New or worsening angina, new transient ischemic attack (TIA), new intermittent claudication or critical limb ischemia with Doppler evidence or total mortality. (NCT00032487)
Timeframe: Post baseline time to first event up to 82 months
| Intervention | participants (Number) |
|---|---|
| Arm 1 | 283 |
| Arm 2 | 312 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
2 reviews available for glimepiride and Diabetic Angiopathies
| Article | Year |
|---|---|
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Topics: Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2013 |
The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
Topics: Carotid Arteries; Chicago; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Human | 2009 |
7 trials available for glimepiride and Diabetic Angiopathies
| Article | Year |
|---|---|
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
Topics: Aged; Biomarkers; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopath | 2017 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Ankle; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Angiop | 2010 |
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Aortography; Biomarkers; Blood Glucose; C-Reactive | 2011 |
Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
Topics: Aged; Aged, 80 and over; Area Under Curve; Blood Glucose; Carbamates; Cardiovascular Diseases; Cross | 2005 |
Predictors of response to glimepiride in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoproteins; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; | 2001 |
6 other studies available for glimepiride and Diabetic Angiopathies
| Article | Year |
|---|---|
Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.
Topics: Aged; Arrhythmias, Cardiac; Cause of Death; Death, Sudden, Cardiac; Diabetic Angiopathies; Female; G | 2018 |
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angio | 2019 |
Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway.
Topics: Blotting, Western; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Ce | 2009 |
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art | 2011 |
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus, | 2011 |
A diabetic woman with worsening heart failure, hunger, and tremor.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gastrointestinal Agents; Heart Failure; Humans; Hy | 2003 |